Top 8 Companies in the Global Epistaxis Device Market

The global epistaxis device market is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032, driven by the rising incidence of epistaxis (nosebleeds) across the globe.

Epistaxis is a medical term used for nosebleeds. Most nosebleeds are mild, self-limiting, and spontaneous, but some can be recurrent. Nosebleeds occur when a blood vessel bursts inside the nose. Epistaxis devices are most widely used for nose bleeding management and, thus, with the rise in functional endoscopic sinus surgery (FESS), the epistaxis device market is witnessing significant growth. As FESS is simple and minimally invasive, it has become the most preferred choice for patients with chronic rhinosinusitis (CRS).

It is estimated that nearly 60% of people will experience a nosebleed at least once in a lifetime. The occurrence of nosebleeds is also commonly recorded in children aged from 2 to 10 years and adults aged between 55 to 80 years old. In July 2023, NasaClip, Inc., a Baltimore-based medical device company that focuses on developing nose bleed management devices launched an innovative easy-to-use device called NasaClip. The device instantly provides constant, comfortable hands-free compression combined with intranasal sponges to stop the bleeding nose. It is the first FDA-approved device that comes with adjustable nasal compression for children. This cutting-edge development is poised to have a significant impact on the epistaxis device market demand triggering competition and more innovations in the market. With curated features such as adjustable compression for children, this innovation is highly capable of being chosen as the first choice of healthcare providers to treat the condition, propelling the market demand.

Major Companies Shaping the Epistaxis Device Market in 2024

1.    Medtronic plc

Medtronic, a leader in medical technology, specialises in a wide range of healthcare solutions, including products for ENT, neurology, and cardiovascular care. In May 2022, Medtronic expanded its ENT portfolio by acquiring Intersect ENT, known for its innovative sinus procedures that improve post-operative outcomes and treat nasal polyps. This acquisition strengthens Medtronic’s position in the epistaxis device market, offering advanced solutions to manage nasal bleeding and sinus-related conditions. With the expanded portfolio, Medtronic is poised to meet the growing demand for effective epistaxis management in the forecast period.

2.    Smith & Nephew plc

Smith & Nephew, a leading medical technology company, provides products for wound management, sports medicine, and orthopaedics. In the epistaxis market, it offers innovative solutions such as nasal packing devices and hemostatic products. These devices are crucial in treating nasal bleeding, offering efficient and effective results while improving patient recovery time and comfort.

3.    Johnson & Johnson (Ethicon)

Johnson & Johnson’s Ethicon division is renowned for its surgical products, including devices for wound closure and hemostasis. In November 2023, Ethicon launched ETHIZIA™, a synthetic hemostat designed for challenging bleeding situations. The product, which stops bleeding in under 30 seconds, can be used in both open and minimally invasive surgeries. This approval reinforces Ethicon’s role in the epistaxis device market, offering surgeons a faster, more effective solution for managing nasal bleeding. The technology’s proven efficacy is expected to enhance market growth by providing advanced hemostatic solutions for epistaxis treatment.

4.    Stryker Corporation

Stryker, a global leader in medical technology, offers a broad range of solutions, including surgical instruments and hemostasis products. In November 2024, Stryker introduced the next generation of SurgiCount+, integrated with Triton technology for improved sponge management and blood loss assessment. This advancement streamlines workflow and enhances surgical precision, providing valuable tools for the management of epistaxis during procedures. The new launch is expected to drive growth in the epistaxis market by facilitating better outcomes and patient safety during nasal surgeries.

5.    Cook Group

Cook Group is a global medical device manufacturer known for its expertise in vascular and interventional procedures. In the epistaxis space, Cook provides advanced devices such as nasal catheters and balloons that offer precise control in managing nasal haemorrhages. Their products are designed to provide efficient bleeding control, improving patient recovery times and surgical outcomes.

6.    Olympus Corporation

Olympus, a pioneer in medical technologies, develops innovative solutions for diagnostic and therapeutic procedures. In February 2022, Olympus received FDA clearance for its CELERIS™ single-use sinus debrider system, designed to enhance sinus surgeries. With a focus on post-operative care, the CELERIS™ system will improve outcomes in the management of nasal bleeding. As market demand for advanced, minimally invasive procedures rises, Olympus’ new product will likely contribute to significant growth in the epistaxis device market, driving more efficient treatments and patient recovery.

7.    Boston Scientific Corporation

Boston Scientific is a prominent player in medical device manufacturing, offering solutions across multiple therapeutic areas. In the epistaxis device market, the company provides a range of products such as nasal balloon catheters and endoscopic devices to control bleeding. Their innovative devices are designed to provide minimal invasiveness and efficient control over nasal bleeding, contributing to faster patient recovery.

8.    Karl Storz SE & Co. KG

Karl Storz is a leading manufacturer of endoscopic equipment. The company offers a range of epistaxis devices designed for minimally invasive procedures, including advanced nasal packing devices, endoscopic tools, and haemostasis products. Their devices aim to reduce bleeding effectively during nasal procedures, enhancing clinical outcomes and patient recovery.